08048035996
Xgeva 120 mg Good Quality Injection to UK - London | Phoenix Exim | Trusted Exporter

1. General Information

Xgeva 120 mg is a prescription medicine containing denosumab, a RANK ligand (RANKL) inhibitor. It is primarily used in patients with cancer affecting the bones or multiple myeloma to reduce the risk of serious skeletal complications.

It is also indicated for adults and skeletally mature adolescents with certain giant cell tumors of bone that cannot be adequately treated with surgery, and for hypercalcemia of malignancy that has not responded adequately to bisphosphonate therapy.

Xgeva should be administered only under the supervision of a qualified healthcare professional.

2. Product Information

  • Brand: Xgeva
  • Active ingredient: Denosumab
  • Strength: 120 mg/1.7 mL
  • Dosage form: Solution for injection
  • Route: Subcutaneous injection
  • Manufacturer/brand owner: Amgen
  • Therapeutic category: Bone-targeting monoclonal antibody
  • Typical oncology schedule: 120 mg once every 4 weeks for several approved indications
  • Administration sites: Upper arm, upper thigh, or abdomen

The medicine is not administered intravenously, intramuscularly, or intradermally.

3. Uses of Xgeva 120 mg

Xgeva may be prescribed for:

  • Prevention of skeletal-related events in patients with multiple myeloma
  • Prevention of fractures and other serious bone complications in patients with bone metastases from solid tumors
  • Treatment of certain unresectable giant cell tumors of bone
  • Treatment of hypercalcemia of malignancy that is refractory to bisphosphonate therapy

In patients with bone metastases, skeletal complications can include fractures, spinal cord compression, bone surgery, and radiation treatment to bones.

4. Benefits of Xgeva 120 mg

When appropriately prescribed, Xgeva can help:

  • Reduce the risk of serious cancer-related bone complications
  • Reduce the likelihood of fractures associated with skeletal disease
  • Help reduce the risk of spinal cord compression
  • Reduce the need for radiation or surgery to affected bones
  • Slow excessive bone breakdown associated with certain cancers
  • Provide a subcutaneous treatment option rather than an intravenous infusion

The specific benefit depends on the patient's diagnosis, cancer type, bone involvement, and overall treatment plan.

5. Side Effects of Xgeva 120 mg

Xgeva can cause side effects, and not every patient experiences them.

Potential adverse effects include:

  • Low calcium levels in the blood
  • Low phosphate levels
  • Fatigue or weakness
  • Nausea
  • Diarrhea
  • Back pain
  • Headache
  • Rash
  • Swelling of the hands or legs
  • Respiratory infections
  • Anemia or reduced blood-cell counts in some patient populations

Serious but less common complications can include severe hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, serious infections, and severe allergic reactions.

6. Common Side Effects

Reported common adverse effects vary according to the condition being treated.

For patients with bone metastases from solid tumors, commonly reported effects include tiredness/weakness, low phosphate levels and nausea.

In multiple myeloma patients, reported effects include diarrhea, nausea, anemia, low platelet counts, low calcium levels, back pain, swelling, upper respiratory tract infection, rash and headache.

Patients should contact their healthcare professional if side effects become severe or persistent.

7. How to Use Xgeva 120 mg

Xgeva is administered by a healthcare professional as a subcutaneous injection.

For multiple myeloma and bone metastases from solid tumors, the recommended dose is generally 120 mg every 4 weeks. Other approved indications can have different dosing schedules, so the prescribing indication must be considered.

Patients should:

  1. Have their treatment prescribed by an appropriate specialist.
  2. Have blood calcium levels checked as recommended.
  3. Receive the injection under medical supervision.
  4. Take calcium and vitamin D supplementation when prescribed.
  5. Attend appointments according to the treatment schedule.

Do not self-administer Xgeva unless specifically trained and instructed by a healthcare professional.

8. How Xgeva Works

Xgeva contains denosumab, which blocks RANK ligand (RANKL).

RANKL is an important signaling molecule involved in the formation and activation of osteoclasts—the cells responsible for breaking down bone. By inhibiting RANKL, denosumab reduces osteoclast activity and therefore slows excessive bone resorption.

This helps protect bone from serious complications associated with certain cancers and other approved conditions.

9. Safety Advice for Xgeva 120 mg

Important safety considerations include:

  • Low blood calcium must be corrected before treatment. Xgeva can significantly reduce calcium levels.
  • Calcium and vitamin D should be taken according to the healthcare professional's instructions.
  • Blood calcium should be monitored as medically appropriate.
  • Tell your doctor if you have kidney problems because severe hypocalcemia can be more likely in patients with impaired kidney function.
  • Maintain good oral hygiene and have appropriate dental examinations.
  • Tell your dentist that you are receiving denosumab.
  • Inform your doctor about planned tooth extraction or dental surgery because of the risk of osteonecrosis of the jaw.
  • Do not combine Xgeva with another denosumab-containing product such as Prolia.
  • Women who can become pregnant should discuss contraception and pregnancy risks with their healthcare professional.
  • Seek urgent medical attention for symptoms of a severe allergic reaction such as breathing difficulty, throat tightness, facial or tongue swelling, hives, or severe rash.
  • Do not stop treatment without discussing it with the treating doctor, because stopping denosumab can increase the risk of vertebral fractures in some patients.

10. Frequently Asked Questions

Q1. What is Xgeva 120 mg used for?
Xgeva is used for several approved bone-related oncology indications, including prevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors. It also has indications for giant cell tumor of bone and certain cases of hypercalcemia of malignancy.

Q2. Is Xgeva 120 mg a tablet?
No. Xgeva 120 mg is supplied as a subcutaneous injection, commonly as 120 mg/1.7 mL.

Q3. How often is Xgeva given?
For multiple myeloma and bone metastases from solid tumors, the usual recommended dose is 120 mg every 4 weeks. Other indications may have different schedules.

Q4. Can Xgeva be given intravenously?
No. Xgeva is intended for subcutaneous administration and should not be administered intravenously, intramuscularly, or intradermally.

Q5. Does Xgeva lower calcium?
Yes. Xgeva can significantly lower blood calcium, which is why calcium levels should be assessed and monitored and calcium/vitamin D may be prescribed.

Q6. Can Xgeva affect the jaw?
Yes. Osteonecrosis of the jaw is a recognized serious adverse effect. Good dental care and communication with the dentist are important.

Q7. Can Xgeva be taken with Prolia?
No. Both contain denosumab, and the product information advises against using Xgeva with another denosumab-containing product.

Q8. Who should administer Xgeva?
Xgeva should be administered by a qualified healthcare professional according to the prescribing information.

11. Substitute for Xgeva 120 mg

The appropriate alternative depends on the patient's diagnosis and clinical circumstances. Zoledronic acid is one bone-targeting medicine that may be considered as an alternative in some patients with bone metastases or multiple myeloma, but it is not a direct substitute for every Xgeva indication.

Another denosumab product, Prolia, is not an interchangeable substitute for Xgeva because it has different approved indications and dosing. The treating oncologist should select any alternative based on the patient's condition, kidney function, calcium status, cancer type, and treatment plan.

12. SEO Keywords

Product Keywords

  • Xgeva 120 mg injection
  • Xgeva 120 mg denosumab injection
  • Denosumab 120 mg injection
  • Xgeva 120 mg vial
  • Xgeva denosumab injection supplier
  • Xgeva 120 mg injection exporter
  • Denosumab injection exporter from India
  • Xgeva 120 mg pharmaceutical supplier
  • Xgeva 120 mg oncology medicine
  • Xgeva 120 mg cancer medicine

B2B & Export Keywords

  • Xgeva 120 mg injection exporter from Nagpur India
  • Xgeva 120 mg wholesale supplier India
  • Denosumab 120 mg injection wholesale supplier
  • Xgeva 120 mg medicine exporter India
  • Xgeva 120 mg injection supplier for USA
  • Xgeva 120 mg supplier for UK
  • Xgeva 120 mg exporter to Australia
  • Xgeva 120 mg supplier to Singapore
  • Xgeva 120 mg exporter to Canada
  • Xgeva 120 mg supplier to South Korea
  • Xgeva 120 mg exporter to UAE
  • pharmaceutical exporter from Nagpur India
  • oncology medicine exporter India
  • cancer medicine supplier India
  • denosumab injection supplier India
  • oncology pharmaceutical wholesale exporter
  • Xgeva 120 mg international pharmaceutical supplier
  • Xgeva 120 mg B2B medicine supplier
  • Xgeva 120 mg bulk pharmaceutical supplier
  • trusted pharmaceutical exporter from India

Phoenix Exim SEO Keywords

  • Phoenix Exim Xgeva 120 mg exporter
  • Phoenix Exim denosumab injection supplier
  • Phoenix Exim oncology medicine exporter Nagpur
  • Phoenix Exim pharmaceutical exporter India
  • Phoenix Exim Xgeva 120 mg supplier
  • Phoenix Exim cancer medicine exporter
  • Phoenix Exim denosumab 120 mg injection
  • trusted medicine exporter from Nagpur India
  • verified pharmaceutical exporter India
  • oncology medicine exporter from Nagpur to USA UK Australia Canada Singapore South Korea UAE
Aug 13th, 2026 3:27 PM

Keywords